Iron Chelation Therapy Global Market Report 2025

The iron chelation therapy market size has grown strongly in recent years. It will grow from $2.51 billion in 2024 to $2.68 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth during the historic period can be attributed to the increasing demand for safer iron removal treatments, rising global rates of blood transfusions, a growing number of chronic anemia cases linked to genetic disorders, increased healthcare spending in emerging markets, and expanding clinical research into iron chelation therapy options.

The iron chelation therapy market size is expected to see strong growth in the next few years. It will grow to $3.46 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The projected growth in the forecast period can be attributed to the rising use of oral chelation medications, increased investments in research for rare diseases, a growing emphasis on personalized treatment approaches, more regulatory approvals for novel therapies, and improved healthcare access in developing countries. Key trends anticipated during this period include advancements in oral chelation drug formulations, the emergence of combination therapy strategies, innovations in targeted drug delivery technologies, the introduction of advanced diagnostic tools for detecting iron overload, and the evolution of patient-centric treatment models.

The rising number of blood transfusions is expected to drive the growth of the iron chelation therapy market in the coming years. Blood transfusion refers to the process of administering donated blood to a patient to restore blood volume or treat medical conditions such as anemia or blood loss. The increase in blood transfusions is primarily attributed to the growing number of complex surgical procedures, which often lead to substantial blood loss requiring transfusion to maintain hemodynamic stability and aid in patient recovery. Iron chelation therapy is essential for eliminating excess iron that accumulates in the body as a result of frequent transfusions. For example, according to the American Red Cross, a U.S.-based nonprofit organization, approximately 16 million blood components are transfused annually in the U.S. Sickle cell disease impacts between 90,000 and 100,000 individuals, with nearly 1,000 infants born with the condition each year, many of whom require lifelong transfusions. As a result, the growing frequency of blood transfusions is fueling the expansion of the iron chelation therapy market.

Leading companies in the iron chelation therapy market are concentrating on the development of next-generation chelators with improved bioavailability to enhance treatment effectiveness, minimize adverse effects, and boost patient adherence. These advanced chelators are formulated to increase absorption and therapeutic efficiency, helping to streamline dosing regimens and promote better compliance in managing iron overload conditions. For example, in March 2023, Chiesi Farmaceutici S.p.A., an Italy-based pharmaceutical firm, received approval from Health Canada for FERRIPROX MR, an extended-release iron chelator taken twice daily, for the treatment of iron overload in patients with thalassemia, sickle cell disease, and other forms of anemia. This product offers greater convenience and sustained support for rare disease treatment. Clinical studies have demonstrated that FERRIPROX MR 1,000 mg is both effective and safe for the intended patient population, with a favorable safety profile for those with iron overload.

In September 2024, Mitem Pharma, a pharmaceutical company based in France, acquired the global rights to DESFERAL (deferoxamine mesylate) from Novartis AG for an undisclosed sum. This acquisition is intended to strengthen Mitem Pharma’s position in the iron chelation therapy market and expand its portfolio with a proven treatment for managing iron overload conditions. Novartis AG, headquartered in Switzerland, is a pharmaceutical company that provides iron chelation therapy solutions.

Major players in the iron chelation therapy market are Pfizer Inc., Bayer AG, Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Zydus Cadila, Balchem, Piramal Pharma Solutions, Vifor Pharma Group, MSN Laboratories, Natco Pharma Ltd., CTX Lifesciences, Nouryon, Tivan Sciences, and Synnat Pharma.

North America was the largest region in the iron chelation therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in iron chelation therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the iron chelation therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Iron chelation therapy is a medical treatment aimed at eliminating excess iron from the body in patients who undergo frequent blood transfusions or suffer from iron overload disorders. This treatment uses chelating agents that bind to surplus iron, enabling its removal from the body through urine or feces. It is commonly used to manage conditions like thalassemia, sickle cell disease, and other chronic anemias to prevent organ damage and improve long-term health outcomes.

The primary types of iron chelation therapy include deferasirox, deferoxamine, and deferiprone. Deferasirox is an oral chelating agent widely used to reduce excess iron in patients receiving regular blood transfusions for conditions such as beta-thalassemia and other chronic anemias. The therapy can be administered via different routes, including oral, parenteral, intravenous, and subcutaneous. Key indications for its application include thalassemia, sickle cell disease, myelodysplastic syndromes (MDS), and non-transfusion-dependent thalassemia (NTDT). It is appropriate for a diverse patient group, encompassing pediatric, adult, elderly, and gender-specific populations, and is utilized across various settings such as hospitals, specialty clinics, homecare environments, and others.

The iron chelation therapy market research report is one of a series of new reports that provides iron chelation therapy market statistics, including the iron chelation therapy industry global market size, regional shares, competitors with the iron chelation therapy market share, detailed iron chelation therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the iron chelation therapy industry. This iron chelation therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The iron chelation therapy market includes revenues earned by entities by providing services such as clinical trial management, personalized treatment planning, drug development, and monitoring iron levels. The market value includes the value of related goods sold by the service provider or included within the service offering. The iron chelation therapy market also includes sales of injectable iron chelators, extended-release formulations, and combination therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.